Cardiac amyloidosis is increasing in incidence and prevalence, but often remains under-recognized, undetected, and undertreated. These findings suggest that cardiovascular (CV) clinicians are less aware and attentive to the substantial morbidity and mortality associated with the progressive nature of cardiac amyloidosis and treatment for this patient population remains suboptimal.
Education is needed on recognizing “red flags” and having heightened suspicion to expedite earlier detection, incorporate guideline recommendations for diagnostic algorithms using non-invasive imaging modalities, and gain knowledge on rapidly emerging disease-modifying targeted treatment strategies for cardiac amyloidosis to improve patient outcomes.
Target Audience:
CV team clinicians including physicians, nurse practitioners, physician assistants and pharmacists who identify and manage patients with cardiac amyloidosis.
Important Dates: Date of Release: 1/09/2023 Term of Approval/Date of Expiration: 1/08/2024 Learner Objective: Upon completion of this activity, the learner should be able to:
Acknowledgements: Educational grant support provided by: Alnylam Pharmaceuticals, Inc.
Faculty:
Richard Kar-Hang Cheng, MD, MSc, FACC
Disclaimer: This activity does not offer credit.